Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04367467 · ClinicalTrials.gov registry record

Effect of PARP Inhibitors on Glomerular Filtration Rate

A clinical trial, sponsored by University of Pennsylvania.

Terminated
Registry status
2
Enrollment target

NCT04367467: Clinical Trial study, sponsored by University of Pennsylvania.

NCT04367467 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04367467 was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
2 participants
Enrollment target

Study Summary

The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function.

Primary Outcome

Change in eGFR from baselineto on-treatment by ≥20% as measured using either cystatin C or 24h urine collection

Interventions

  • OTHER Kidney Function Test

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2020-02-03
Est. Completion 2021-07-01
University of Pennsylvania

1,423 total trials

Why NCT04367467 stopped before completion

NCT04367467 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Kidney Function Test is the first listed.

NCT04367467 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04367467 about?

NCT04367467 is a clinical study titled "Effect of PARP Inhibitors on Glomerular Filtration Rate". The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function.

What is the current status of trial NCT04367467?

This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-02-03. Estimated completion is 2021-07-01.

What interventions are being tested in trial NCT04367467?

The interventions under investigation include: Kidney Function Test (OTHER).

Who is sponsoring clinical trial NCT04367467?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04367467, the US trial registry maintained by the National Library of Medicine. NCT04367467 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.